Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Risk Partners on Going Public and the capital market blog on prospectus liability
insurance

Over the past few months, we have expanded our expertise in the Prospectus liability insurance with a broad audience on two renowned platforms. Here is an overview:

  • Capitalmarket.blog
    In the article "POSI insurance - the protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies that are active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence.

  • GoingPublic Magazine
    In "Liability risks in uplisting and private placements", we focus on the special risks that arise in private placements and the switch to regulated market segments. Here, too, we emphasize how well thought-out prospectus liability insurance can create the necessary security for issuers.

From our projects and the special features of POSI and D&O insurance as claims-made insurances, we know how important it is to have such an insurance program ideally in place. 24 months in advance structure. It is therefore important for us to share our knowledge and expertise so that companies are optimally prepared for the challenges.

🔍 How can we help you? Whether you are planning an IPO, preparing a private placement or want to protect your company against potential liability risks: We provide you with comprehensive advice on Prospectus liability insurance and develop the optimum solution for your requirements.

👉 Get in touch with us today!

Also read our other blog posts

Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
Being Public

"I believe in a strong IPO comeback in 2024" - Interview Platform Life Sciences

Risk Partners in the trade press. Florian was approached by the journalists from Plattform Life Sciences for an interview on our view of 2024 and the development of Risk Partners over the past year. In addition to challenging claims, product innovations (e.g. all about POSI insurance) from Risk Partners, Florian also discusses our motives for the "team up" with the fantastic colleagues from Atrialis GmbH - experts in clinical trials. Click here for Florian's interview. Read the interview

Read more "
Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "
IPO

New: Risk Partners POSI Insurance for MiCAR White Paper

MiCAR Compliance? We Cover the Risk! The MiCAR Regulation (EU 2023/1114) exposes crypto-asset service providers and whitepaper authors to significant liability risks. Incomplete, inaccurate, or misleading information in white papers can have significant consequences for Crypto-Asset Service Providers (CASP) and authors—ranging from regulatory sanctions to civil claims. Our solution: Risk Partners Tech POSI MiCAR Whitepaper Protect 2025 The creation and publication of white papers under MiCAR entails complex liability pitfalls: In addition to civil claims (e.g., under the German Civil Code) and criminal risks, there is a threat of

Read more "